Aegis Capital Lifts PT on Valeant (VRX) to $180; Q4, FY13 Results Solid, M&A Still in the Mix

February 27, 2014 9:40 AM

Aegis Capital boosts its price target on Valeant Pharmaceuticals (NYSE: VRX) from $160 up to $180, while maintaining its Buy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found